Formula I Compounds Targeting HCV NS5B Polymerase
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hepatitis C virus (HCV) infection are limited by the lack of effective vaccines and therapies, particularly for genotype 1, which has a low sustained virologic response rate and severe side effects, necessitating the development of improved antiviral drugs with better efficacy and safety profiles.
Innovation Solution
Development of novel compounds of formula I, which are effective against HCV, including pharmaceutically acceptable salts, that target specific mechanisms of action, binding, inhibition efficacy, target selectivity, solubility, and safety profiles, potentially used in combination with existing treatments like interferon and ribavirin.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments (pegylated alpha-interferon and ribavirin) are used, then HCV infection can be treated, but sustained virologic response rate is low (approximately 50% for genotype 1) and severe side effects occur
Solution Approach 1:
The patent modifies the chemical structure of NS5B polymerase inhibitors by changing parameters such as substituting aromatic rings with heteroaromatic rings, adjusting side chain lengths, and modifying functional groups at specific positions (R1-R6, Q, X, Z in formula I). These parameter changes optimize the compounds for genotype 1 HCV, achieving higher sustained virologic response rates while reducing side effects compared to conventional interferon-based therapies.
Solution Approach 2:
The invention creates composite molecular structures by combining multiple functional moieties within a single compound molecule. The compounds of formula I integrate diverse structural elements (aromatic/heteroaromatic rings, side chains, functional groups) that work synergistically to inhibit NS5B polymerase activity, providing both high efficacy and improved safety profiles.
2Reliability
If genotype 1 HCV is treated with conventional therapies, then treatment is attempted, but elimination of virus is achieved for only approximately 50% of patients
Solution Approach 1:
The patent optimizes the compounds specifically for genotype 1 HCV by introducing genotype-specific structural features. The formula I compounds incorporate specific substituent patterns (R1-R6, Q, X, Z) that enhance binding affinity and inhibitory activity against genotype 1 NS5B polymerase, achieving virus elimination rates exceeding 50% for this difficult-to-treat genotype while maintaining safety.
3Adaptability or versatility
If existing antiviral treatments are used, then HCV infection is addressed, but lack of vaccine and limited therapeutic options remain
Solution Approach 1:
The patent divides the HCV polyprotein into functional segments and targets specific segments (NS5B polymerase) with selective inhibitors. By focusing on this specific viral protein segment, the compounds provide targeted therapy that complements existing treatments and expands therapeutic options without compromising efficacy.
Data Source
AI summary
The disclosure provides compounds of formula I, including pharmaceutically acceptable salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.